Matthew A. Taylor

Matthew A. Taylor

Auto-generated profile, based on publicly available information

Matthew A. Taylor

Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, 6439 Garners Ferry Road, Columbia, SC, 29209, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2018 in Apoptosis
Verified
Journal Article
Closed access
PDF file
MTMatthew A. Taylor
Matthew A. Taylor
BDBhaskar Das
Bhaskar Das
Swapan RaySwapan Ray
Swapan Ray

20 July 2019 in Neuroimmunology and Neuroinflammation
Verified
Journal Article
Open access
PDF file
CMChristopher H. Merritt
Christopher H. Merritt
MTMatthew A. Taylor
Matthew A. Taylor
CYCaleb J. Yelton
Caleb J. Yelton
Swapan RaySwapan Ray
Swapan Ray
Neuroimmunology and Neuroinflammation is an open access journal, with focuses on neuroimmunology and neuroinflammation research, and coverage extending to other basic and clinical studies related to neuroscience.

22 April 2019 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
MTMatthew A. Taylor
Matthew A. Taylor
FKFiras Khathayer
Firas Khathayer
Swapan RaySwapan Ray
Swapan Ray

31 January 2020 in Apoptosis
Verified
Journal Article
Closed access
PDF file
FKFiras Khathayer
Firas Khathayer
MTMatthew A. Taylor
Matthew A. Taylor
Swapan RaySwapan Ray
Swapan Ray

7 December 2020 in The Ultrasound Journal
Verified
Journal Article
Open access
PDF file
MTMatthew A. Taylor
Matthew A. Taylor
CMChristopher H. Merritt
Christopher H. Merritt
PRPhilip J. Riddle
Philip J. Riddle
CDCarter J. DeGennaro
Carter J. DeGennaro
KBKeith R. Barron
Keith R. Barron
Undifferentiated abdominal pain is a common presentation often requiring immediate medical or surgical intervention. Providing an accurate diagnosis involves a detailed patient history and thorough physical exam. Point of care ultrasound is gaining acceptance as a rapid diagnostic tool that can be used to accurately detect life-threatening conditions while potentially avoiding unnecessary radiation exposure and facilitating rapid treatment. Detection of pneumoperitoneum with point-of-care ultrasound is a simple procedure that relies heavily on the experience of the investigating practitioner. Standard technique involves placing a high-frequency linear-array transducer in the right upper quadrant, where abdominal free air is most likely to accumulate. Detection of the ‘gut point’, which is the transition of abdominal wall sliding to lack thereof in a single image, is the pathognomonic finding of pneumoperitoneum. If visualization is difficult, moving the patient to the left lateral decubitus position or using the scissors technique can provide additional image views. This representative case report and review highlights the use of abdominal POCUS for the diagnosis of pneumoperitoneum. Ultrasound should continue to be explored by clinicians to narrow the differential diagnosis of acute abdominal pain.

31 July 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CBCharles L. Bennett
Charles L. Bennett
BSBenjamin Schooley
Benjamin Schooley
MTMatthew A. Taylor
Matthew A. Taylor
BWBartlett J. Witherspoon
Bartlett J. Witherspoon
AGAshley Godwin
Ashley Godwin
BCBrian Chen
Brian Chen
Oncology-associated adverse drug/device reactions can be fatal. Some clinicians who treat single patients with severe oncology-associated toxicities have researched case series and published this information. We investigated motivations and experiences of select individuals leading such efforts. Clinicians treating individual patients who developed oncology-associated serious adverse drug events were asked to participate. Inclusion criteria included having index patient information, reporting case series, and being collaborative with investigators from two National Institutes of Health funded pharmacovigilance networks. Thirty-minute interviews addressed investigational motivation, feedback from pharmaceutical manufacturers, FDA personnel, and academic leadership, and recommendations for improving pharmacovigilance. Responses were analyzed using constant comparative methods of qualitative analysis. Overall, 18 clinicians met inclusion criteria and 14 interviewees are included. Primary motivations were scientific curiosity, expressed by six clinicians. A less common theme was public health related (three clinicians). Six clinicians received feedback characterized as supportive from academic leaders, while four clinicians received feedback characterized as negative. Three clinicians reported that following the case series publication they were invited to speak at academic institutions worldwide. Responses from pharmaceutical manufacturers were characterized as negative by 12 clinicians. One clinician’s wife called the post-reporting time the “Maalox month,” while another clinician reported that the manufacturer collaboratively offered to identify additional cases of the toxicity. Responses from FDA employees were characterized as collaborative for two clinicians, neutral for five clinicians, unresponsive for negative by six clinicians. Three clinicians endorsed developing improved reporting mechanisms for individual physicians, while 11 clinicians endorsed safety activities that should be undertaken by persons other than a motivated clinician who personally treats a patient with a severe adverse drug/device reaction. Our study provides some of the first reports of clinician motivations and experiences with reporting serious or potentially fatal oncology-associated adverse drug or device reactions. Overall, it appears that negative feedback from pharmaceutical manufacturers and mixed feedback from the academic community and/or the FDA were reported. Big data, registries, Data Safety Monitoring Boards, and pharmacogenetic studies may facilitate improved pharmacovigilance efforts for oncology-associated adverse drug reactions. These initiatives overcome concerns related to complacency, indifference, ignorance, and system-level problems as barriers to documenting and reporting adverse drug events- barriers that have been previously reported for clinician reporting of serious adverse drug reactions.